Israel: Pfizer vaccine reduced by 39% against SARS-CoV-2

This percentage, for the period between 20 June and 17 July in Israel, is significantly lower than the 64% mentioned from 6 June to 3 July and the 94,3% measured from May 2 to June 5.

pfizer vaccine Covid-19, Pfizer, SARS-CoV-2, efficacy, vaccine, Israel, pandemic

The effectiveness of the Pfizer / BioNTech vaccine against SARS-CoV-2 infection fell to 39% between June 20 and July 17 in Israel, the Ministry of Health announced on Thursday, noting that this finding is recorded. at a time when the most contagious Delta variant is spreading.

Prevention of serious forms

This percentage is significantly lower than the 64% that was mentioned from June 6 to July 3 and the 94,3% that was measured from May 2 to June 5.

However, the effectiveness of the US-German consortium in preventing serious forms of COVID-19 It is estimated that it reaches 91,4% and its effectiveness in preventing hospital admissions is estimated to reach 88%, according to calculations published by the ministry.

Since the start of the immunization campaign in Israel on 20 December 2020, more than 5,75 million people, or 61,6% of the population, have received the first dose of the vaccine, of which 5,28 million and the second.

The evolution of the pandemic

In the past 24 hours, 1.275 cases of SARS-CoV-2 were diagnosed, with the total number of infections reaching 856.827, while three more patients with COVID-19 succumbed to the pandemic death toll of 6.457.

The number of active cases rose to 9.742, the highest level since March 27.

In addition, the number of patients treated in a serious condition increased to 75 (+7).

in.gr